Project Mosaic Launches to Bring “Biopsies” to ALS Drug Development
August 21, 2024 13:10 ET
|
Project Mosaic
Project Mosaic is proud to announce the launch of a groundbreaking initiative aimed at revolutionizing ALS drug development.
Muscular Dystrophy Association International Association of Fire Fighters Launch 420 Fill the Boot Fundraisers in Cities Across America Labor Day Weekend for the Muscular Dystrophy Association
August 19, 2024 09:15 ET
|
Muscular Dystrophy Association
New York, Aug. 19, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) in partnership with the International Association of Fire Fighters (IAFF) kick off more than 420 Fill the Boot...
Tiziana Life Sciences Appoints New Chief Executive Officer
August 19, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Registration Now Open for the 2025 MDA Clinical & Scientific Conference Featuring the Latest Innovations in Neuromuscular Disease Research and Care with Global Leaders, March 16-19 in Dallas, TX
July 30, 2024 11:53 ET
|
Muscular Dystrophy Association
New York, July 30, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), convener of the largest global gathering of the neuromuscular disease community, announced today that...
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
June 11, 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
PathMaker Neurosystems Announces $2.16 Million Award from U.S. Department of Defense for ALS Clinical Trial
June 05, 2024 06:00 ET
|
PathMaker Neurosystems Inc.
PathMaker Neurosystems receives $2.16 million award from United States Department of Defense for an expanded ALS clinical trial of its MyoRegulator device
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
June 04, 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
AB Science fournit un résumé de la conférence virtuelle qui s'est tenue le 30 mai 2024, faisant le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
May 31, 2024 10:30 ET
|
AB Science
COMMUNIQUE DE PRESSE RESUME DE LA CONFERENCE VIRTUELLE DU 30 MAI 2024 FAISANT LE POINT SUR LA DEMANDE D'AUTORISATION CONDITIONNELLE DE MISE SUR LE MARCHE DU MASITINIB DANS LE TRAITEMENT...
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
May 31, 2024 10:30 ET
|
AB Science
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC...
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
May 30, 2024 16:51 ET
|
Biogen Inc.
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen’s third rare disease therapy to be approved in the...